Trials / Unknown
UnknownNCT06105658
Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML
A Clinical Study to Evaluate the Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Acute Myelocytic Leukemia
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Anhui Provincial Hospital · Other Government
- Sex
- All
- Age
- 14 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study aimed to evaluate the safety and efficacy of unrelated umbilical cord blood microtransplantation in the treatment of AML patients by observing the factors related to the efficacy and adverse reactions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Unrelated umbilical cord blood | The requirements of unrelated umbilical cord blood: recipient-donor HLA match is 0-3/10, same blood type. |
| DRUG | Venetoclax | Patients will be treated with Venetoclax (100 mg on day 1, 200 mg on day 2 and 400 mg on days 3 to 21) |
| DRUG | Decetabine | Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7) |
| DRUG | Azacitidine | Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7) |
Timeline
- Start date
- 2023-10-01
- Primary completion
- 2024-02-01
- Completion
- 2026-02-01
- First posted
- 2023-10-27
- Last updated
- 2023-10-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06105658. Inclusion in this directory is not an endorsement.